Previous studies have proven that graphene oxide (GO) regulates abscisic acid (ABA) and indole-3-acetic acid (IAA) contents and modulates plant root growth. To better understand the mechanism of ...plant growth and development regulated by GO and crosstalk between ABA and GO, Zhongshuang No. 9 seedlings were treated with GO and ABA. The results indicated that GO and ABA significantly affected the morphological properties and endogenous phytohormone contents in seedlings, and there was significant crosstalk between GO and ABA. ABA treatments combined with GO led to a rapid decrease in triphenyltetrazolium chloride (TTC) reduction intensity, and the inhibitory effect was enhanced with increasing ABA concentration. The treatments significantly affected the transcriptional levels of some key genes involved in the ABA, IAA, cytokinin (CTK), salicylic acid (SA), and ethane (ETH) pathways and increased the ABA and gibberellin (GA) contents in rapeseed seedlings. The effects of the treatments on the IAA and CTK contents were complex, but, importantly, the treatments suppressed root elongation. Correlation analysis also indicated that the relationship between root length and IAA/ABA could be described by a polynomial function: y = 88.11x2 − 25.15x + 4.813(R² = 0.912). The treatments increased the ACS2 transcript abundance for ETH biosynthesis and the ICS1 transcriptional level of the key genes involved in salicylic acid (SA) biosynthesis, as well as the downstream signaling genes CBP60 and SARD1. This finding indicated that ABA is an important factor regulating the effects of GO on the growth and development of Brassica napus L., and that ETH and SA pathways may be potential pathways involved in the response of rape seedlings to GO treatment.
Aerosolised Ad5-nCoV is the first approved mucosal respiratory COVID-19 vaccine to be used as a booster after the primary immunisation with COVID-19 vaccines. This study aimed to evaluate the safety ...and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster.
This is an open-label, parallel-controlled, phase 4 randomised trial enrolling healthy adult participants (≥18 years) who had completed a two-dose primary immunisation and a booster immunisation with inactivated COVID-19 vaccines (CoronaVac only) at least 6 months before, in Lianshui and Donghai counties, Jiangsu Province, China. We recruited eligible participants from previous trials in China (NCT04892459, NCT04952727, and NCT05043259) as cohort 1 (with the serum before and after the first booster dose available), and from eligible volunteers in Lianshui and Donghai counties, Jiangsu Province, as cohort 2. Participants were randomly assigned at a ratio of 1:1:1, using a web-based interactive response randomisation system, to receive the fourth dose (second booster) of aerosolised Ad5-nCoV (0·1 mL of 1·0 × 10
viral particles per mL), intramuscular Ad5-nCoV (0·5 mL of 1·0 × 10
viral particles per mL), or inactivated COVID-19 vaccine CoronaVac (0·5 mL), respectively. The co-primary outcomes were safety and immunogenicity of geometric mean titres (GMTs) of serum neutralising antibodies against prototype live SARS-CoV-2 virus 28 days after the vaccination, assessed on a per-protocol basis. Non-inferiority or superiority was achieved when the lower limit of the 95% CI of the GMT ratio (heterologous group vs homologous group) exceeded 0·67 or 1·0, respectively. This study was registered with ClinicalTrials.gov, NCT05303584 and is ongoing.
Between April 23 and May 23, 2022, from 367 volunteers screened for eligibility, 356 participants met eligibility criteria and received a dose of aerosolised Ad5-nCoV (n=117), intramuscular Ad5-nCoV (n=120), or CoronaVac (n=119). Within 28 days of booster vaccination, participants in the intramuscular Ad5-nCoV group reported a significantly higher frequency of adverse reactions than those in the aerosolised Ad5-nCoV and intramuscular CoronaVac groups (30% vs 9% and 14%, respectively; p<0·0001). No serious adverse events related to the vaccination were reported. The heterologous boosting with aerosolised Ad5-nCoV triggered a GMT of 672·4 (95% CI 539·7-837·7) and intramuscular Ad5-nCoV triggered a serum neutralising antibody GMT of 582·6 (505·0-672·2) 28 days after the booster dose, both of which were significantly higher than the GMT in the CoronaVac group (58·5 48·0-71·4; p<0·0001).
A heterologous fourth dose (second booster) with either aerosolised Ad5-nCoV or intramuscular Ad5-nCoV was safe and highly immunogenic in healthy adults who had been immunised with three doses of CoronaVac.
National Natural Science Foundation of China, Jiangsu Provincial Science Fund for Distinguished Young Scholars, and Jiangsu Provincial Key Project of Science and Technology Plan.
Studies have shown that serum response factor is beneficial for axonal regeneration of peripheral nerves. However, its role after central nervous system injury remains unclear. In this study, we ...established a rat model of T9-T10 spinal cord transection injury. We found that the expression of serum response factor in injured spinal cord gray matter neurons gradually increased with time, reached its peak on the 7th day, and then gradually decreased. To investigate the role of serum response factor, we used lentivirus vectors to overexpress and silence serum response factor in spinal cord tissue. We found that overexpression of serum response factor promoted motor function recovery in rats with spinal cord injury. Qualitative observation of biotinylated dextran amine anterograde tracing showed that overexpression of serum response factor increased nerve fibers in the injured spinal cord. Additionally, transmission electron microscopy showed that axon and myelin sheath morphology was restored. Silencing serum response factor had the opposite effects of overexpression. These findings suggest that serum response factor plays a role in the recovery of motor function after spinal cord injury. The underlying mechanism may be related to the regulation of axonal regeneration.
The certification of immunogenicity consistency at different production scales is indispensable for the quality control of vaccines.
A randomized, double-blind immunobridging trial in healthy adults ...aged 18-59 was divided into Scale A (50 L and 800 L) and Scale B (50 L and 500 L) based on vaccine manufacturing scales. Eligible participants in Scale A were randomly assigned to receive the single-dose recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) of different scales at a 1:1 ratio, as was Scale B. The primary endpoint was the geometric mean titer (GMT) of anti-live SARS-CoV-2-specific neutralizing antibodies (NAb) 28 days post-vaccination.
1,012 participants were enrolled, with 253 (25%) per group. The post-vaccination GMTs of NAb were 10.72 (95% CI: 9.43, 12.19) and 13.23 (11.64, 15.03) in Scale A 50 L and 800 L, respectively; 11.64 (10.12, 13.39) and 12.09 (10.48, 13.95) in Scale B 50 L and 500 L, respectively. GMT ratios in Scale A and B have a 95% CI of 0.67-1.5. Most adverse reactions were mild or moderate. 17 of 18 participants reported non-vaccination-related serious adverse reactions.
The Ad5-nCoV in the scale-up production of 500 L and 800 L showed consistent immunogenicity with the original 50 L production scale, respectively.
In order to precisely assess gene expression level, a suitable internal reference gene must be chosen to quantify real-time reverse transcription polymerase chain reaction (RT-qPCR) data. For ...greenbug, Schizaphis graminum, a suitable reference gene for assessing the level of transcriptional expression of target genes has yet to be explored. In our study, eight reference genes, elongation fator 1 beta (Ef1β), TATA box binding protein (TBP), alpha-tubulin (α-TUB), 18S ribosomal (18S), 28S ribosomal (28S), glyceraldehyde-3-phosphate (GAPDH), actin (ACT), and ribosomal protein L18 (RPL18) were evaluated in S. graminum at different developmental stages, tissues, and insecticide treatments. To further explore whether these genes are suitable to serve as internal control, three software-based approaches (geNorm, BestKeeper, and NormFinder), ΔCt method, and one web-based comprehensive tool (RefFinder) were employed to analyze and rank the tested genes. The optimal number of reference genes was determined using the geNorm program, and the suitability of particular reference genes was empirically validated according to normalized gene expression data of three target genes, heat shock protein gene (HSP70), cytocrome P450 gene (SgraCYP18A1), and glutathione S-transferase (GST). We found that the most suitable reference genes varied considerably under different experimental conditions. For developmental stages, α-TUB and 28S were the optimal reference genes; for different tissues, 18S and ACT were suitable reference genes; for insecticide treatments, 28S and α-TUB were suitable for normalizations of expression data. In addition, 28S and α-TUB were the suitable reference gene as they had the most stable expression among different developmental stages, tissues and insecticide treatments. This should be useful for the selection of the suitable reference genes to obtain reliable RTqPCR data in the gene expression of S. graminum.
Background. Seven persons in one family living in eastern China developed fever and thrombocytopenia during May 2007, but the initial investigation failed to identify an infectious etiology. In ...December 2009, a novel bunyavirus (designated severe fever with thrombocytopenia syndrome bunyavirus SFTSV) was identified as the cause of illness in patients with similar clinical manifestations in China. We reexamined this family cluster for SFTSV infection. Methods. We analyzed epidemiological and clinical data for the index patient and 6 secondary patients. We tested stored blood specimens from the 6 secondary patients using real time reverse transcription polymerase chain reaction (RT-PCR), viral culture, genetic sequencing, micro-neutralization assay (MNA), and indirect immunofluorescence assay (IFA). Results. An 80-year-old woman with fever, leucopenia, and thrombocytopenia died on 27 April 2007. Between 3 and 7 May 2007, another 6 patients from her family were admitted to a local county hospital with fever and other similar symptoms. Serum specimens collected in 2007 from these 6 patients were positive for SFTS viral RNA through RT-PCR and for antibody to SFTSV through MNA and IFA. SFTSV was isolated from 1 preserved serum specimen. The only shared characteristic between secondary patients was personal contact with the index patient; none reported exposure to suspected animals or vectors. Conclusions. Clinical and laboratory evidence confirmed that the patients of fever and thrombocytopenia occurring in a family cluster in eastern China in 2007 were caused by a newly recognized bunyavirus, SFTSV. Epidemiological investigation strongly suggests that infection of secondary patients was transmitted to family members by personal contact.
In this report, we integrated a photoswitchable quencher, a highly emissive yet pH sensitive fluorophore, and a water-soluble polymer with controlled hydrophilicity into a functional nanosystem. The ...photoswitching quencher is based on dithienylethene (DTE) unit, while the pH-sensitive emitter is naphthalimide (NI) unit and the water-soluble polymer is obtained from polymerization of N-isopropylacrylamide (NIPAM). Together, these three units create a novel super-resolution lysosome highlighter, although individually none can function as a lysotracker. Because the emitter is sensitive to pH, the resulting polymer becomes highly fluorescent in acidic lysosomes. In addition, photoswitching regulates the fluorescence on and off and thus enables super-resolution localization of fluorescent polymers with sub-40 nm spatial resolution in imaging subcellular organelles. Thus, the concept presented here, including the photoswitchable DTE-pH-sensitive NI dyad, is promising to guide the development of future-generation super-resolution imaging agents.
Since the Anthropocene, biodiversity loss owing to human activity and climate change has worsened. Quercus gilva is an evergreen oak species native to China, Japan, and South Korea and is threatened ...by a long history of human impact. The purpose of this study was to (1) reassess the threatened category of Q. gilva based on a detailed survey, and (2) identify the genetic structure and diversity of Q. gilva based on genomic data. First, we conducted a detailed survey of the populations in China. Second, we collated all the literature and information. Finally, genome-wide genetic variation was analyzed based on 65 individuals from 22 populations. We found that Q. gilva has suffered rapid population decline, and at present, most populations are very small. The evolutionary path of Q. gilva was from the southwest to east of China and then to Japan and South Korea. Quercus gilva showed no distinct genetic structure and had a relatively low genetic diversity. Among the 22 populations, most populations in southwestern China, South Korea, and Japan had high genetic diversity. The populations in Jingning (Zhejiang province; ZJN), Wuyuan (Jinaxi province; JWY), and Zherong (Fujian province; FZR) suffered a strong bottleneck. In conclusion, Q. gilva is an endangered species native to East Asia. Because of the very low genetic diversity of Q. gilva and most populations are small, we need to (1) strengthen the protection of this species, (2) conduct conservation actions with in-situ reinforcement populations, and (3) select populations with high genetic diversity as provenances for afforestation efforts. Finally, we suggest that in the future, genetic diversity should be considered as the sixth criterion for IUCN to evaluate the threatened category.
Abstract
COVID-19 vaccines from multiple manufacturers are needed to cope with the problem of insufficient supply. We did two single-center, randomised, double-blind, placebo-controlled phase 1 and ...phase 2 trials to assess the safety, tolerability and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older in China. Eligible participants were enrolled, the ratio of candidate vaccine and placebo within each dose group was 3:1 (phase 1) or 5:1 (phase 2). From August 28, 2020, 168 participants were sequentially enrolled and randomly assigned to receive the low dose vaccine, high dose vaccine or placebo with the schedule of 0, 28 days or 0, 14, 28 days in phase 1 trial. From November 18, 2020, 960 participants were randomly assigned to receive the low dose vaccine, high dose vaccine or placebo with the schedule of 0, 21 days or 0, 14, 28 days in phase 2 trial. The most common solicited injection site adverse reaction within 7 days in both trials was pain. The most common solicited systematic adverse reactions within 7 days were fatigue, cough, sore throat, fever and headache. ELISA antibodies and neutralising antibodies increased at 14 days, and peaked at 28 days (phase 1) or 30 days (phase 2) after the last dose vaccination. The GMTs of neutralising antibody against live SARS-CoV-2 at 28 days or 30 days after the last dose vaccination were highest in the adult high dose group (0, 14, 28 days), with 102.9 (95% CI 61.9–171.2) and 102.6 (95% CI 75.2–140.1) in phase 1 and phase 2 trials, respectively. Specific T-cell response peaked at 14 days after the last dose vaccination in phase 1 trial. This vaccine is safe, and induced significant immune responses after three doses of vaccination.
PDF
